The Role of a Public-Private Partnership in HIV Cure

Mike McCune, MD, PhD
University of California, San Francisco
The Goal

To discover, develop, test, and distribute “cure” interventions that are:

Safe
Effective
Stable
Scalable
Affordable
Hurdles to cross
Science – Which mechanisms enable HIV persistence? Which can be interrupted?
Hurdles to cross

**Science** – Which mechanisms enable HIV persistence? Which can be interrupted?

**People** – How can we create and incentivize collaborative, multidisciplinary teams to test hypotheses?
Hurdles to cross

Science – Which mechanisms enable HIV persistence? Which can be interrupted?

People – How can we create and incentivize collaborative, multidisciplinary teams to test hypotheses?

Process – With what infrastructure, which cohorts, and which bioassay will potential “cures” be prioritized?
Hurdles to cross

**Science** – Which mechanisms enable HIV persistence? Which can be interrupted?

**People** – How can we create and incentivize collaborative, multidisciplinary teams to test hypotheses?

**Process** – With what infrastructure, which cohorts, and which bioassay will potential “cures” be prioritized?

**Distribution** – If have a “cure” in hand, how can we assure its world-wide distribution?
The Process of Bringing Better Therapies to the World
The Early Stages of this Process Are Done Well by Academic Centers

Solo scientists

Single discipline

Discovery driven

Innovative

Academic Center
The Later Stages Are Better Performed by Biotech/Pharma

- Multidisciplinary teams
- Practical solutions
- Profit oriented

Community → Clinic → Biotech/Pharma
A New Model Is Needed to Bring “Cures” to Resource-Poor Settings

Discovery driven

Innovative

Academic Center

Clinic

Community

Bench

Multidisciplinary teams

Practical solutions

Biotech/Pharma
Public-Private Partnership

Definition

An informal or formal arrangement between

one or more public sector entities
and

one or more private sector entities

To achieve a public health objective or to produce a health-related product or service for the public good.

To share certain risks and to exchange intellectual property, financial, in-kind, and/or human resources in any mutually agreed upon proportion.
Public-Private Partnership: Benefits

Created to provide urgently needed therapies for neglected diseases:

- Malaria
- Tuberculosis
- Dengue
- Leishmaniasis
- African trypanosomiasis
- Chagas

Enable **effective merger of strengths** in academia, industry, and non-governmental organizations.
• National Institutes of Health – “Cure Collaboratories”

• International AIDS Society

• Forum for Collaborative HIV Research

• American Foundation for AIDS Research
HIV Cure Public-Private Partnership Initiative

November 2013: The Annenberg Foundation Trust at Sunnylands convened an international group of leaders from science, government, philanthropy, and industry to address issues associated with HIV “cure.”
HIV Cure Public-Private Partnership Initiative

November 2013: The Annenberg Foundation Trust at Sunnylands convened an international group of leaders from science, government, philanthropy, and industry to address issues associated with HIV “cure.”

Key question:
How can these groups work together to most efficiently deliver safe, effective, and affordable cure interventions for use around the world?
HIV Cure Public-Private Partnership Initiative

Resolved

• To identify, test, and distribute interventions that will, in conjunction with effective antiretroviral therapy, lead to a drug-free remission (or “cure”) in HIV-infected individuals.

• To work together to develop new pathways to amplify existing HIV cure efforts.

• To overcome barriers to success through greater collaboration.
HIV Cure Public-Private Partnership Initiative

**Status**

- Growing
- Designed to be inclusive
- Governance procedures being put into place
- Focused on three general topics...
Development of a “Roadmap:”

Highlighting priority areas of activity, identifying major barriers to developing, producing, and distributing an HIV cure, and setting forth major milestones associated with scientific, clinical, regulatory, production, and distribution/access efforts that will guide stakeholder efforts over the next 20 years.
Discovery and standardization of a biomarker:

Focused on the development and standardization of novel methods for quantifying HIV persistence that are:

- capable of quantifying the total body burden of SIV in relevant long-term treated nonhuman primates
- predictive of time to virologic rebound during carefully-monitored analytic treatment interruptions
- blood-based
- high throughput
- applicable for routine clinical settings
Establishment of a business case:

What are the financial and societal implications of achieving a “cure” for HIV disease that is accessible in both high and low resource settings?

What are the incentives for entities within and across sectors to form collaborative bonds with one another to reach this goal?
HIV Cure Public-Private Partnership Initiative

For more information

Ellen LaPointe, JD, is serving as the Project Director for the initiative and can be reached at ellenlapointe@gmail.com.